8-K: OmniAb Reports In-Line Second Quarter Results, Cites Strong Deal Flow Potential

OmniAb announced its second quarter 2024 financial results, reporting revenue of $7.6 million and a net loss of $13.6 million, while highlighting new partnerships and clinical progress.

Summary

• OmniAb's second quarter 2024 revenue reached $7.6 million, an increase from $6.9 million in the same period last year, primarily due to accelerated recognition of deferred service revenue.
• Research and development expenses were $13.9 million, slightly down from $14.1 million in the second quarter of 2023.
• General and administrative expenses decreased to $8.0 million from $8.7 million year-over-year, mainly due to lower share-based compensation and non-recurring prior-year costs.
• The company reported a net loss of $13.6 million, or $0.13 per share, compared to a net loss of $14.7 million, or $0.15 per share, in the second quarter of 2023.
• Year-to-date revenue was $11.4 million, down from $23.9 million in 2023, due to the recognition of a $10 million milestone in the prior year.
• The net loss for the first six months of 2024 was $32.6 million, or $0.32 per share, compared to a net loss of $20.8 million, or $0.21 per share, in the same period of 2023.
• OmniAb had $57.2 million in cash, cash equivalents, and short-term investments as of June 30, 2024.
• The company expects total operating expenses in 2024 to be slightly less than in 2023 and anticipates cash use in 2025 to be substantially lower than in 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to in-line results, strong deal flow potential, and clinical progress in partner programs. However, the increased net loss year-to-date and some program discontinuations temper the overall optimism.

Positives

• Second quarter results were in-line with expectations, supporting the full-year outlook.
• The company experienced strong business development momentum, with potential for a record year in deal flow.
• OmniAb has a growing number of active partners and programs, indicating strong market adoption of its technology.
• Several partner programs are showing positive clinical progress, including acasunlimab and sugemalimab.
• The company's cash balance and expected cash from operations are projected to fund operations for the foreseeable future.
• Operating expenses are expected to be slightly lower in 2024 compared to 2023.
• Cash use is expected to be substantially lower in 2025 compared to 2024.

Negatives

• Year-to-date revenue decreased to $11.4 million from $23.9 million in 2023, primarily due to the recognition of a large milestone payment in the prior year.
• The net loss for the first six months of 2024 was $32.6 million, compared to $20.8 million in the same period of 2023.
• Amortization of intangible assets increased due to a $1.2 million impairment related to legacy unpartnered programs.
• GSK discontinued a small molecule Nav1.1 sodium channel modulator program, although OmniAb retains co-ownership of the intellectual property.
• Roche is returning rights to a pre-clinical small molecule targeting Kv7.2, although this is not due to scientific reasons.

Risks

• The company's future success depends on the acceptance of its technology platform by new and existing partners.
• Biopharmaceutical development is inherently uncertain, and there are risks associated with changes in technology.
• The competitive environment in the life sciences and biotechnology platform market poses a risk.
• Failure to maintain, protect, and defend intellectual property rights could negatively impact the company.
• Unstable market and economic conditions may have adverse consequences on the business, financial condition, and stock price.
• The company may use its capital resources sooner than expected.

Future Outlook

OmniAb expects total operating expenses in 2024 to be slightly less than in 2023 and anticipates cash use in 2025 to be substantially lower than in 2024. The company's current cash balance and cash from operations are expected to provide sufficient capital to fund operations for the foreseeable future.

Management Comments

• Second quarter results were in-line with our expectations and support our view of the full year, said Matt Foehr, Chief Executive Officer of OmniAb.
• With recent momentum in business development, 2024 has the potential to be a record year in terms of deal flow, which we believe is driven by the quality and differentiation of our technology platforms and by the superior execution of our team.

Industry Context

This announcement reflects the ongoing trend of pharmaceutical and biotech companies seeking innovative technology platforms for drug discovery. OmniAb's focus on diverse antibody repertoires and advanced screening technologies positions it well in the competitive landscape. The partnerships and clinical progress updates highlight the increasing demand for novel therapeutic modalities, including bispecific antibodies and antibody-drug conjugates.

Comparison to Industry Standards

• OmniAb's revenue growth in Q2 2024, while positive year-over-year, is modest compared to some larger biotech companies that have commercialized products. For example, companies like Regeneron or Genmab, with approved drugs, often report significantly higher revenue figures.
• The net loss for the first six months of 2024 is substantial, indicating that OmniAb is still in a growth phase and investing heavily in R&D. This is typical for companies in the early stages of drug discovery and development, similar to companies like Xencor or IGM Biosciences.
• The number of active partners (83) and programs (333) is a strong indicator of market adoption, comparable to other platform technology companies like AbCellera or Twist Bioscience, which also focus on providing discovery services to the industry.
• The clinical progress of partner programs, such as the 69% overall survival rate for acasunlimab, is a positive sign and aligns with the industry's focus on developing effective cancer therapies. This is comparable to other companies developing bispecific antibodies, such as Amgen or Roche.
• The discontinuation of the GSK ion channel program and the return of rights by Roche are not uncommon in the industry, as drug development is inherently risky. Many programs fail in preclinical or early clinical stages, and companies often need to adjust their portfolios. This is similar to the experiences of many other biotech companies.

Stakeholder Impact

• Shareholders may view the in-line results and strong deal flow potential positively, but the increased net loss year-to-date could be a concern.
• Employees may be encouraged by the company's growth and the potential for a record year in deal flow.
• Partners will be interested in the continued development of OmniAb's technology and the progress of their programs.
• Customers may benefit from the advancements in drug discovery enabled by OmniAb's platform.
• Suppliers may see increased business opportunities as OmniAb expands its operations.

Next Steps

• OmniAb will continue to advance its technology platform and seek new partnerships.
• The company will monitor the progress of its partner programs, including the planned Phase 3 trial for acasunlimab.
• OmniAb will continue to develop its xPloration technology platform.
• The company will continue to pursue commercial partnerships for sugemalimab in various regions.

Key Dates

Keywords

OmniAb, antibody discovery, biologics, therapeutic development, platform technology, clinical trials, partnerships, licensing, bispecific antibodies, drug conjugates, ion channels, xPloration, OmniRat, OmniChicken, OmniMouse